Information de reference pour ce titreAccession Number: | 00000779-199804130-00012.
|
Author: | Kronn, David MB, BCh; Jansen, Valerie MS; Ostrer, Harry MD
|
Institution: | From the Division of Medical Genetics, New York Medical College, Valhalla, NY (Dr Kronn), and the Human Genetics Program, New York University Medical Center, New York, NY (Ms Jansen and Dr Ostrer).
|
Title: | Carrier Screening for Cystic Fibrosis, Gaucher Disease, and Tay-Sachs Disease in the Ashkenazi Jewish Population: The First 1000 Cases at New York University Medical Center, New York, NY.[Article]
|
Source: | Archives of Internal Medicine. 158(7):777-781, April 13, 1998.
|
Abstract: | Background: By late 1993, the genes for cystic fibrosis and Gaucher disease and the mutations common among Ashkenazi Jews had been identified. In response to these advances, heterozygote screening for cystic fibrosis and Gaucher disease was added to the more than 20-year-old Tay-Sachs disease screening program at New York University Medical Center, New York, NY.
Objective: To review the outcomes from the first 1000 patients screened through this program.
Methods: Patients and their referring physicians were informed about the new carrier tests. At the time of screening, patients could choose their tests (hexosaminidase A by enzyme analysis for Tay-Sachs disease or mutation analysis for cystic fibrosis and Gaucher disease). All partners of Tay-Sachs and cystic fibrosis carriers were tested. Prenatal diagnosis was offered and performed for carrier couples or mixed-marriage couples in whom the Ashkenazi Jewish partner was a carrier of Gaucher disease. Outcomes were measured by: (1) choice of tests, (2) decisions regarding prenatal diagnosis, and (3) phenotypes of children born to patients who underwent screening.
Results: The majority of Ashkenazi Jewish patients chose to have testing for all 3 diseases. If they previously underwent screening for Tay-Sachs disease, then they chose to undergo testing for cystic fibrosis and Gaucher disease. All carrier couples for each of these diseases went on to have prenatal testing. All mixed-marriage couples in whom the Jewish partner was found to be a carrier for Gaucher disease chose to have prenatal diagnosis. One fetus was identified as having cystic fibrosis. Since the program was initiated, no Ashkenazi Jewish baby has been born with any of these diseases at New York University Medical Center.
Conclusions: New tests can be readily incorporated into established heterozygote screening programs. The Ashkenazi Jewish population described herein tends to choose testing for all conditions for which heterozygote screening is available.
Arch Intern Med.1998;158:777-781
Copyright 1998 by the American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use. American Medical Association, 515 N. State St, Chicago, IL 60610.
|
Author Keywords: | Cystic Fibrosis; Gaucher Disease; Genetic Screening; Jews; Prenatal Diagnosis; Tay-Sachs Disease.
|
References: | 1. Kaback M, Lim-Steele J, Dabholkar D, Brown D, Lew N, Zeiger K. Tay-Sachs disease: carrier screening, prenatal diagnosis and the molecular era: an international perspective, 1970 to 1993. JAMA. 1993;270:2307-2315.
2. Riordan JR, Rommens JM, Kerem B, et al. Identification of the cystic fibrosis gene: cloning and characterization of the complementary DNA. [published correction appears in Science. 1989;245:1437]. Science. 1989;245:1066-1073.
3. Sorge J, West C, Westwood B, Beutler E. Molecular cloning and nucleotide sequence of the human glucocerebrosidase gene. Proc Natl Acad Sci U S A. 1985;82:7289-7293.
4. Abeliovich D, Lavon IP, Lerer I, et al. Screening for five mutations detects 97% of cystic fibrosis chromosomes and predicts a carrier frequency of 1:29 in the Jewish Ashkenazi population. Am J Hum Genet. 1992;51:951-956.
5. Beutler E, Nguyen NJ, Henneberger MW, et al. Gaucher disease: gene frequencies in the Ashkenazi Jewish population. Am J Hum Genet. 1993;52:85-88.
6. Beutler E, Gelbart T. Gaucher disease mutations in non-Jewish patients. Br J Haematol. 1993;85:401-405.
7. Shuber AP, Skoletsky J, Stern R, Handelin BL. Efficient 12-mutation testing in the CFTR gene: a general model for complex mutation analysis. Hum Mol Genet. 1993;2:153-158.
8. Kaback M. Thermal fractionation of serum hexosaminidase: applications in heterozygote detection and diagnosis of Tay-Sachs disease. Methods Enzymol. 1972;28:862-867.
9. Abeliovich D, Quint A, Eeinberg N, et al. Cystic fibrosis heterozygote screening in the orthodox community of Ashkenazi Jews: the Dor Yeshorim approach and heterozygote frequency. Eur J Hum Genet. 1996;4:338-341.
10. DeMarchi JM, Caskey CT, Richards CS. Population-specific screening by mutation analysis for diseases frequent in Ashkenazi Jews. Hum Mutat. 1996;8:116-125.
11. Beutler E. The cost of treating Gaucher disease. Nat Med. 1996;2:523-524.
12. NIH Technology Assessment Conference on Gaucher Disease. Current issues in diagnosis and treatment. Presented at: National Institutes of Health Technology Assessment Conference; February 27, 1995; Bethesda, Md.
13. NIH Technology Assessment Panel on Gaucher Disease. Gaucher disease: current issues in diagnosis and treatment. JAMA. 1996;275:548-553.
14. Witt DR, Schaefer C, Hallam P, et al. Cystic fibrosis heterozygote screening in 5,161 pregnant women. Am J Hum Genet. 1996;58:823-835.
15. Schwartz M, Brandt NJ, Skovby F. Screening for carriers of cystic fibrosis among pregnant women: a pilot study. Eur J Hum Genet. 1993;1:239-244.
16. Brock DJ. Carrier screening for cystic fibrosis. Prenat Diagn. 1994;14:1243-1252.
17. Mennie ME, Gilfillan A, Compton M, et al. Prenatal screening for cystic fibrosis. Lancet. 1992;40:214-216.
18. Miedzybrodzka ZH, Hall MH, Mollison J, et al. Antenatal screening for carriers of cystic fibrosis: randomised trial of stepwise v couple screening. BMJ. 1995;10:353-357.
19. Jung U, Urner U, Grade K, Coutelle C. Acceptability of carrier screening for cystic fibrosis during pregnancy in a German population. Hum Genet. 1994;94:19-24.
20. Loader S, Caldwell P, Koryza A, et al. Cystic fibrosis carrier population screening in the primary care setting. Am J Hum Genet. 1996;59:234-247.
21. Clayton EW, Hannig VL, Pfotenhauer JP, Parker RA, Campbell III PW, Phillips III JA. Lack of interest by nonpregnant couples in population-based cystic fibrosis carrier screening. Am J Hum Genet. 1996;58:617-627.
22. Matalon R, Michals K, Kaul R. Canavan disease: from spongy degeneration to molecular analysis. J Pediatr. 1995;127:511-517.
23. Kaul R, Gao GP, Aloya M, Balamurugan K, Petrosky A, Michals K. Canavan disease: mutations among Jewish and non-Jewish patients. Am J Hum Genet. 1994;55:34-41.
24. Kronn D, Oddoux C, Phillips J, Ostrer H. Prevalence of Canavan disease heterozygotes in the New York metropolitan Ashkenazi Jewish population. Am J Hum Genet. 1995;57:1250-1252.
25. Motulsky AG. Jewish diseases and origins. Nat Genet. 1995;9:99-101.
26. Verlander PC, Kaporis A, Liu Q, Zhang Q, Seligsohn U, Auerbach AD. Carrier frequency of the IVS4 + 4 A rarr T mutation of the Fanconi anemia gene FAC in the Ashkenazi Jewish population. Blood. 1995;86:4034-4038.
27. Whitney MA, Jakobs P, Kaback M, Moses RE, Grompe M. The Ashkenazi Jewish Fanconi anemia mutation: incidence among patients and carrier frequency in the at-risk population. Hum Mutat. 1994;3:339-341.
28. Ellis NA, Groden J, Ye TZ, et al. The Bloom's syndrome gene product is homologous to RecQ helicases. Cell. 1995;83:655-666.
29. Levran O, Desnick RJ, Schuchman EH. Type A Niemann-Pick disease: a frameshift mutation in the acid sphingomyelinase gene (fsP330) occurs in Ashkenazi Jewish patients. Hum Mutat. 1993;2:317-319.
|
Language: | English.
|
Document Type: | Original Investigation.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0003-9926
|
NLM Journal Code: | 0372440, 7fs
|
Annotation(s) | |
|
|